Supernus Pharmaceuticals (SUPN) News Today → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free SUPN Stock Alerts $29.10 -0.06 (-0.21%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNMay 16, 2024 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Sees Unusually-High Trading VolumeSupernus Pharmaceuticals (NASDAQ:SUPN) Sees Strong Trading VolumeMay 10, 2024 | finance.yahoo.comSupernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)May 10, 2024 | finance.yahoo.comSupernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...May 9, 2024 | globenewswire.comSupernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresMay 9, 2024 | finance.yahoo.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comSupernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | investorplace.comSUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comSupernus Announces First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comSupernus's ADHD Drug Qelbree To Be Commercialized In Latin America By M8 PharmaMay 7, 2024 | prnewswire.comM8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin AmericaMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNMay 2, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsMay 1, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsMay 1, 2024 | globenewswire.comBusy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree StoryMay 1, 2024 | marketbeat.comSupernus Pharmaceuticals (SUPN) Scheduled to Post Quarterly Earnings on WednesdaySupernus Pharmaceuticals (NASDAQ:SUPN) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589006)April 29, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of InvestorsApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNApril 27, 2024 | marketbeat.comLouisiana State Employees Retirement System Purchases New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Louisiana State Employees Retirement System purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 27,300 shares of the specialtyApril 24, 2024 | globenewswire.comSupernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024April 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNApril 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNApril 19, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - SUPNApril 15, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)April 15, 2024 | marketbeat.comPhocas Financial Corp. Sells 35,507 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Phocas Financial Corp. lessened its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,559 shares of the specialty pharmaceutical company'sApril 10, 2024 | uk.investing.comSupernus receives FDA rejection for Parkinson's treatment, submits additional dataApril 9, 2024 | yahoo.comUS FDA declines to approve Supernus' Parkinson's combination again (April 8)April 8, 2024 | finanznachrichten.deSupernus Pharmaceuticals, Inc.: Supernus Provides Regulatory Update for SPN-830April 8, 2024 | msn.comSupernus stock slides as FDA rejects Parkinson's disease infusion deviceApril 8, 2024 | finance.yahoo.comSupernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's DiseaseApril 8, 2024 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down to $33.55Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down to $33.55April 8, 2024 | reuters.comU.S. FDA declines to approve Supernus' drug-device combination for Parkinson's diseaseApril 8, 2024 | globenewswire.comSupernus Provides Regulatory Update for SPN-830April 6, 2024 | marketbeat.comAssenagon Asset Management S.A. Buys New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Assenagon Asset Management S.A. purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 36,254 shares of theMarch 26, 2024 | insidertrades.comPadmanabh P. Bhatt Sells 14,491 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) StockMarch 25, 2024 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Stock Price Down 3.9% Following Insider SellingSupernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 3.9% After Insider SellingMarch 25, 2024 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $511,677.21 in StockSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh P. Bhatt sold 14,491 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $35.31, for a total value of $511,677.21. Following the transaction, the vice president now owns 8,570 shares in the company, valued at $302,606.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.March 22, 2024 | insidertrades.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 12,364 SharesMarch 21, 2024 | finanznachrichten.deSupernus Pharmaceuticals, Inc.: Supernus Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 16, 2024 | investing.comSupernus Pharmaceuticals executive trades company stockMarch 16, 2024 | finance.yahoo.comSUPN Apr 2024 29.000 callMarch 16, 2024 | insidertrades.comPadmanabh P. Bhatt Sells 3,884 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) StockMarch 15, 2024 | investing.comSupernus Pharmaceuticals executive sells over $2.1m in stockMarch 11, 2024 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Polar Capital Holdings PlcPolar Capital Holdings Plc raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 10.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,654,470 shares of the specialty phMarch 6, 2024 | globenewswire.comSupernus to Participate in Two Upcoming Investor ConferencesMarch 4, 2024 | seekingalpha.comSupernus Pharmaceuticals: Moving Through An 'Inflection Year'March 3, 2024 | marketbeat.comInvesco Ltd. Sells 64,791 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Invesco Ltd. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 682,691 shares of the specialty pharmaceutical company's stock after selFebruary 29, 2024 | finance.yahoo.comSupernus Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Connor Clark & Lunn Investment Management Ltd. raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 43.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 80,584 shares of the specialty pharmaceFebruary 28, 2024 | globenewswire.comSupernus to Participate in the TD Cowen 44th Annual Healthcare Conference Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking: One AI startup's revenue could surge 4,735% (Ad)Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner. Click here to discover the AI chip company SUPN Media Mentions By Week SUPN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUPN News Sentiment▼0.340.42▲Average Medical News Sentiment SUPN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUPN Articles This Week▼23▲SUPN Articles Average Week Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PCRX News INVA News ARQT News OCUL News ORIC News PHAT News CORT News KPTI News BTAI News PRGO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SUPN) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceDems have chosen Biden replacement?Paradigm PressBill Gates is all about this tiny $2 stockTimothy SykesDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
